about
A case-control study of maternal periconceptual and pregnancy recreational drug use and fetal malformation using hair analysisDevelopment and validation of a liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method for simultaneous analysis of 10 amphetamine-, methamphetamine- and 3,4-methylenedioxymethamphetamine-related (MDMA) analytOpium use during pregnancy and risk of preterm delivery: A population-based cohort studyChronic in utero buprenorphine exposure causes prolonged respiratory effects in the guinea pig neonate.Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United StatesDrug addiction during pregnancy: correlations between the placental health and the newborn's outcome - elaboration of a predictive score.Maternal methadone dose, placental methadone concentrations, and neonatal outcomes.Molecular mechanisms of HIV-1 mother-to-child transmission and infection in neonatal target cells.Long-term outcomes among drug-dependent mothers treated in women-only versus mixed-gender programs.Methadone, cocaine, opiates, and metabolite disposition in umbilical cord and correlations to maternal methadone dose and neonatal outcomesDrug testing for newborn exposure to illicit substances in pregnancy: pitfalls and pearls.Development and validation of a liquid chromatography mass spectrometry assay for the simultaneous quantification of methadone, cocaine, opiates and metabolites in human umbilical cord.Simultaneous quantification of methadone, cocaine, opiates, and metabolites in human placenta by liquid chromatography-mass spectrometryShould pregnant women with substance use disorders be managed differently?Cannabinoid concentrations in hair from documented cannabis users.Refining Measurement of Substance Use Disorders Among Women of Child-Bearing Age Using Hospital Records: The Development of the Explicit-Mention Substance Abuse Need for Treatment in Women (EMSANT-W) Algorithm.Identifying the substance abuse treatment needs of caregivers involved with child welfare.Validated LC-MS-MS Method for Multiresidual Analysis of 13 Illicit Phenethylamines in Amniotic Fluid.Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration.Prenatal methamphetamine exposure, home environment, and primary caregiver risk factors predict child behavioral problems at 5 years.Maternal and neonatal effects of substance abuse during pregnancy: our ten-year experience.Respiratory effects of chronic in utero methadone or morphine exposure in the neonatal guinea pig.Methamphetamine detection in maternal and neonatal hair: implications for fetal safety.Determination of amphetamine and methamphetamine in umbilical cord using liquid chromatography-tandem mass spectrometry.Bioanalytical methods for the determination of cocaine and metabolites in human biological samples.Bioanalysis during pregnancy: recent advances and novel sampling strategies.Maternal and neonatal hair and breast milk in the assessment of perinatal exposure to drugs of abuse.Epigenetic Influences During the Periconception Period and Assisted Reproduction.The Prevalence and Impact of Substance Use Disorder and Treatment on Maternal Obstetric Experiences and Birth Outcomes Among Singleton Deliveries in Massachusetts.MOMS Plus: A public health program for substance using pregnant inmates in an urban jail.Trends of Neonatal Abstinence Syndrome Epidemic and Maternal Risk Factors in Florida.Prevalence of prenatal exposure to substances of abuse: questionnaire versus biomarkers.Cocaine causes atrial Purkinje fiber damage.Incidence of fetal drug exposure in Alabama: 2004-2011.Development of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Four Cannabinoids in Umbilical Cord Tissue.Simultaneous determination of opiates, methadone, amphetamines, cocaine, and metabolites in human placenta and umbilical cord by LC-MS/MS.Development of the drug-exposed infant identification algorithm (DEIIA) and its application to measuring part C early intervention referral and eligibility in Massachusetts, 1998-2005.Psychopharmacologic treatment of children prenatally exposed to drugs of abuse.Meconium drug testing reveals maternal misuse of medicinal opioids among addicted mothers.
P2860
Q28544639-E68E9365-58E9-462F-8626-416DA5668B92Q33439633-F625943C-230B-49AC-B897-516054D36E46Q33610542-1B1E5FBA-C3FB-4508-B629-30D83C39F225Q33787848-970F3781-38FE-4503-896B-A4F5E37B2E13Q34182409-63A41BF5-6862-4067-86F4-9D8399012323Q34613716-CA33CEB6-A4B1-48FE-BE91-3DA82BC79916Q34626408-79556D95-F911-44B8-ACA2-ACA2DC1D5838Q34626428-34D92604-F11C-458C-A981-2E187BC6A95CQ35091308-C53BCCDA-4469-4206-BC57-D71CAD0071DCQ35112886-F1C3650B-7E9C-4757-A9FD-2FD6563918A2Q35113865-BC74712C-0F24-46E2-A52B-9964CE7FD2A1Q35184678-92826B7F-C856-4C51-BC28-4B6770FD744AQ35215304-B05E15EC-DFD2-4C34-8D44-8AD9E6459D27Q36464851-62E57966-FA52-457C-A156-01D8640B6469Q36508389-11981354-A588-44A4-80A3-4723BCBDCFDEQ36713316-EEE26124-5C13-4ADF-8EF9-9623865702CEQ36812095-2D86BC11-B312-42AE-A73F-E34A63E1F1AFQ36948814-24B23F74-CA95-451B-B988-2FFA6C3E815BQ36992670-F0DB76AD-DC64-49F7-838D-BD9AE189D9F5Q37040422-3A047152-9981-403F-80C4-1203007C42F6Q37041159-6274E457-D60A-4878-967E-4E59AE7EDD25Q37147635-B525A47B-3728-4B04-9BF2-9A1E5AE19B5AQ37174701-8FB07600-7321-4D5C-B929-A2352494FF61Q37434781-AA34693F-B6BA-4E29-96B0-E122D6037031Q37810146-47496A00-FE06-44FD-9F1D-8B674110DE93Q38296225-0DB688BD-140F-4FBA-B018-F10A2138FC18Q38516618-10DDB7F5-3C96-4151-B421-A5C1BB31E0DAQ38634063-288B6716-51DB-49F4-8270-E828B3CAA3CEQ39198442-1247AADF-572E-480C-853B-3CDF7C4EB123Q39762808-840F2367-9ADA-4F51-82FA-EDE1297FD7F6Q40202958-9FEF5655-D9FD-4E45-A721-52E2C39DAC78Q42628106-710E0D26-1405-48BD-A809-DDEE68A3D3EDQ43146245-561046A1-6DBE-4243-AC34-31AE9FF17BF1Q46317467-EFAA9CD6-34EA-4F9C-B707-0285D5830D68Q47667155-148893AD-2C2A-42F8-8539-E4BA89408555Q48091451-BB90894F-37F4-42D7-8E0D-C5AA56FA1014Q50120151-7B83BBDF-A49F-4B1C-9569-1FEC901B1D71Q50595227-EECB9DF2-2EF3-4CC7-8470-3A589E72C502Q52302206-1739C33E-61E0-4D59-B165-118C3FD7F870
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Drug abuse's smallest victims: in utero drug exposure.
@ast
Drug abuse's smallest victims: in utero drug exposure.
@en
Drug abuse's smallest victims: in utero drug exposure.
@nl
type
label
Drug abuse's smallest victims: in utero drug exposure.
@ast
Drug abuse's smallest victims: in utero drug exposure.
@en
Drug abuse's smallest victims: in utero drug exposure.
@nl
prefLabel
Drug abuse's smallest victims: in utero drug exposure.
@ast
Drug abuse's smallest victims: in utero drug exposure.
@en
Drug abuse's smallest victims: in utero drug exposure.
@nl
P1476
Drug abuse's smallest victims: in utero drug exposure.
@en
P2093
Marilyn A Huestis
Robin E Choo
P356
10.1016/S0379-0738(02)00160-3
P577
2002-08-01T00:00:00Z